A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel dose study of two doses of R935788 [R 788, fostamatinib] in rheumatoid arthritis patients failing to respond to methotrexate.

Trial Profile

A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel dose study of two doses of R935788 [R 788, fostamatinib] in rheumatoid arthritis patients failing to respond to methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TASKI-2
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 May 2011 Health-related quality-of-life results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 05 May 2011 AstraZeneca added as trial sponsor and lead trial cenre as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top